Insmed Gains 0.24% on $210M Volume Slides to 484th in U.S. Trading Rankings

On September 23, 2025, , . The stock ranked 484th in trading volume among U.S. equities. Market movements were influenced by strategic updates in its therapeutic pipeline and regulatory developments.

Recent corporate activity highlighted Insmed’s focus on advancing its AURIS pathway, . Analysts noted the data could strengthen negotiations with payers in high-margin markets. Additionally, a partnership with a European biotech firm for co-development of a respiratory drug candidate added momentum to investor sentiment.

Technical indicators showed mixed signals, . However, . Market participants remain cautious ahead of Q3 earnings, .

To run this back-test accurately, I’ll need clarification on three parameters: (1) the market universe (e.g., U.S.-listed stocks), (2) pricing conventions (e.g., close-to-close execution), and (3) portfolio weighting methodology (e.g., equal-weight vs. volume-weighted). Once these details are confirmed, .